These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

697 related items for PubMed ID: 26299293

  • 1. Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
    Carbon M, Kapoor S, Sheridan E, Al-Jadiri A, Azzo S, Sarkaria T, Kane JM, Saito E, Correll CU.
    J Am Acad Child Adolesc Psychiatry; 2015 Sep; 54(9):718-727.e3. PubMed ID: 26299293
    [Abstract] [Full Text] [Related]

  • 2. Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.
    Al-Dhaher Z, Kapoor S, Saito E, Krakower S, David L, Ake T, Kane JM, Correll CU, Carbon M.
    J Child Adolesc Psychopharmacol; 2016 Jun; 26(5):458-70. PubMed ID: 27093218
    [Abstract] [Full Text] [Related]

  • 3. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
    Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Martinez-Garcia O, Neergaard KD, Tabares-Seisdedos R, Crespo-Facorro B.
    Psychopharmacology (Berl); 2017 Sep; 234(17):2563-2570. PubMed ID: 28567698
    [Abstract] [Full Text] [Related]

  • 4. Neurological Adverse Effects of Antipsychotics in Children and Adolescents.
    Garcia-Amador M, Merchán-Naranjo J, Tapia C, Moreno C, Castro-Fornieles J, Baeza I, de la Serna E, Alda JA, Muñoz D, Andrés Nestares P, Cantarero CM, Arango C.
    J Clin Psychopharmacol; 2015 Dec; 35(6):686-93. PubMed ID: 26505569
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.
    Johnsen E, Kroken RA, Wentzel-Larsen T, Jørgensen HA.
    BMC Psychiatry; 2010 Mar 24; 10():26. PubMed ID: 20334680
    [Abstract] [Full Text] [Related]

  • 7. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y, Kim E, You M, Pikalov A, Tran QV.
    J Med Econ; 2009 Jun 24; 12(2):104-13. PubMed ID: 19527195
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
    Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK.
    JAMA; 2009 Oct 28; 302(16):1765-73. PubMed ID: 19861668
    [Abstract] [Full Text] [Related]

  • 10. Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998 Oct 28; 59 Suppl 12():23-7. PubMed ID: 9766616
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I, IC-SOHO Study Group.
    J Clin Psychiatry; 2004 Mar 28; 65(3):312-21. PubMed ID: 15096069
    [Abstract] [Full Text] [Related]

  • 13. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
    Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Vázquez-Bourgon J, Suárez-Pinilla P, Romero-Jiménez R, Setién Suero E, Ayesa-Arriola R, Crespo-Facorro B.
    Int J Neuropsychopharmacol; 2020 Apr 23; 23(4):217-229. PubMed ID: 31974576
    [Abstract] [Full Text] [Related]

  • 14. Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study.
    Chyou TY, Nishtala R, Nishtala PS.
    Pharmacoepidemiol Drug Saf; 2020 Jun 23; 29(6):692-700. PubMed ID: 32301237
    [Abstract] [Full Text] [Related]

  • 15. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
    Moteshafi H, Stip E.
    Expert Opin Drug Saf; 2012 Sep 23; 11(5):713-32. PubMed ID: 22913713
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
    N Engl J Med; 2005 Sep 22; 353(12):1209-23. PubMed ID: 16172203
    [Abstract] [Full Text] [Related]

  • 17. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
    Correll CU, Leucht S, Kane JM.
    Am J Psychiatry; 2004 Mar 22; 161(3):414-25. PubMed ID: 14992963
    [Abstract] [Full Text] [Related]

  • 18. Absence of Change in Corrected QT Interval in Children and Adolescents Receiving Antipsychotic Treatment: A 12 Month Study.
    Alda JA, Muñoz-Samons D, Tor J, Merchán-Naranjo J, Tapia-Casellas C, Baeza I, Calvo-Escalona R, Castro-Fornieles J, Martínez-Cantarero C, Andrés-Nestares P, Fernández-Avilés F, Arango C.
    J Child Adolesc Psychopharmacol; 2016 Jun 22; 26(5):449-57. PubMed ID: 26779966
    [Abstract] [Full Text] [Related]

  • 19. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
    Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA.
    World J Biol Psychiatry; 2009 Jun 22; 10(4 Pt 3):710-8. PubMed ID: 18803070
    [Abstract] [Full Text] [Related]

  • 20. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR.
    J Am Pharm Assoc (2003); 2007 Jun 22; 47(3):373-8. PubMed ID: 17510032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.